Evidence map›Paper›PMID 42335229›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Restriction-modification systems are required for

Selma Metaane, H Steven Seifert

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Restriction-modification systems are required forProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Restriction-modification systems are required forbioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Selma MetaaneDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.ORCID 0000-0002-2543-1646
H Steven SeifertDepartment of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.ORCID 0000-0001-8651-0375

Funding

Mechanisms of Gonococcal Pilin Antigenic/Phase VariationR37AI033493 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hank S. SEIFERT · 2003 to 2026
$10.1M
Targeting the functions of the gonococcal Type lV pilusR01AI146073 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hank S. SEIFERT · 2020 to 2026
$3.3M
An unbiased screen to identify Neisseria gonorrhoeae genes important for survival to neutrophil killing mechanismsR21AI148981 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SEIFERT, HANK S. · 2020 to 2021
$437k
HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) R01AI146073HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) R21AI148981HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID) R37AI033493
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigenic VariationDNA Restriction-Modification EnzymesFimbriae ProteinsNeisseria gonorrhoeaeBase SequenceFimbriae, BacterialDNA Restriction-Modification EnzymesFimbriae ProteinspilE protein, Neisseria gonorrhoeaeantigenic variationmethylationNeisseriapilusrestriction

Identifiers

PMID42335229
PMCPMC13321361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.